Ongoing replication stress tolerance and clonal T cell responses distinguish liver and lung recurrence and outcomes in pancreatic cancer.

阅读:17
作者:Link Jason M, Eng Jennifer R, Pelz Carl, MacPherson-Hawthorne Kevin, Worth Patrick J, Sivagnanam Shamaline, Keith Dove J, Owen Sydney, Langer Ellen M, Grossblatt-Wait Alison, Salgado-Garza Gustavo, Creason Allison L, Protzek Sara, Egger Julian, Holly Hannah, Heskett Michael B, Chin Koei, Kirchberger Nell, Betre Konjit, Bucher Elmar, Kilburn David, Hu Zhi, Munks Michael W, English Isabel A, Tsuda Motoyuki, Goecks Jeremy, Demir Emek, Adey Andrew C, Kardosh Adel, Lopez Charles D, Sheppard Brett C, Guimaraes Alex, Brinkerhoff Brian, Morgan Terry K, Mills Gordon B, Coussens Lisa M, Brody Jonathan R, Sears Rosalie C
Patients with metastatic pancreatic ductal adenocarcinoma survive longer if disease spreads to the lung but not the liver. Here we generated overlapping, multi-omic datasets to identify molecular and cellular features that distinguish patients whose disease develops liver metastasis (liver cohort) from those whose disease develops lung metastasis without liver metastases (lung cohort). Lung cohort patients survived longer than liver cohort patients, despite sharing the same tumor subtype. We developed a primary organotropism (pORG) gene set enriched in liver cohort versus lung cohort primary tumors. We identified ongoing replication stress response pathways in high pORG/liver cohort tumors, whereas low pORG/lung cohort tumors had greater densities of lymphocytes and shared T cell clonal responses. Our study demonstrates that liver-avid pancreatic ductal adenocarcinoma is associated with tolerance to ongoing replication stress, limited tumor immunity and less-favorable outcomes, whereas low replication stress, lung-avid/liver-averse tumors are associated with active tumor immunity that may account for favorable outcomes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。